1. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK.
- Author
-
Brown NR, Korolchuk S, Martin MP, Stanley WA, Moukhametzianov R, Noble MEM, and Endicott JA
- Subjects
- Adenosine Triphosphate chemistry, Animals, Binding, Competitive, CDC2 Protein Kinase, CDC2-CDC28 Kinases genetics, Carrier Proteins genetics, Cattle, Cell Cycle Proteins genetics, Conserved Sequence, Crystallography, X-Ray, Cyclin A chemistry, Cyclin A genetics, Cyclin B genetics, Cyclin-Dependent Kinase 2 chemistry, Cyclin-Dependent Kinase 2 genetics, Cyclin-Dependent Kinases antagonists & inhibitors, Cyclin-Dependent Kinases genetics, Gene Expression, Humans, Kinetics, Models, Molecular, Peptides chemical synthesis, Peptides chemistry, Protein Binding, Protein Kinase Inhibitors chemistry, Protein Stability, Protein Structure, Secondary, Protein Structure, Tertiary, Recombinant Fusion Proteins genetics, Substrate Specificity, CDC2-CDC28 Kinases chemistry, Carrier Proteins chemistry, Cell Cycle Proteins chemistry, Cyclin B chemistry, Cyclin-Dependent Kinases chemistry, Recombinant Fusion Proteins chemistry
- Abstract
CDK1 is the only essential cell cycle CDK in human cells and is required for successful completion of M-phase. It is the founding member of the CDK family and is conserved across all eukaryotes. Here we report the crystal structures of complexes of CDK1-Cks1 and CDK1-cyclin B-Cks2. These structures confirm the conserved nature of the inactive monomeric CDK fold and its ability to be remodelled by cyclin binding. Relative to CDK2-cyclin A, CDK1-cyclin B is less thermally stable, has a smaller interfacial surface, is more susceptible to activation segment dephosphorylation and shows differences in the substrate sequence features that determine activity. Both CDK1 and CDK2 are potential cancer targets for which selective compounds are required. We also describe the first structure of CDK1 bound to a potent ATP-competitive inhibitor and identify aspects of CDK1 structure and plasticity that might be exploited to develop CDK1-selective inhibitors.
- Published
- 2015
- Full Text
- View/download PDF